Nasdaq · Healthcare
HERON THERAPEUTICS, INC. /DE/ (HRTX)
As-reported financials and recent SEC filings for HERON THERAPEUTICS, INC. /DE/, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$154.9M
Net income
$-20.2M
Net margin
-13.0%
Diluted EPS
$-0.12
ROE
-140.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | $40.3M |
| Operating income | $-2.5M | $-11.5M | $-110.6M | $-174.7M | $-217.8M |
| Net income | $-20.2M | $-13.6M | $-110.6M | $-182.0M | $-220.7M |
| Diluted EPS | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-0.00 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-25
View on EDGAR →42026-06-17
View on EDGAR →8-K2026-06-16
View on EDGAR →42026-06-08
View on EDGAR →8-K2026-06-02
View on EDGAR →SCHEDULE 13G/A2026-05-13
View on EDGAR →10-Q2026-05-11
View on EDGAR →8-K2026-05-11
View on EDGAR →Largest Healthcare peers
Go deeper on HRTX
Search HERON THERAPEUTICS, INC. /DE/’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.